Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30014266 | 1.00 | MLYCD (0.38) | MLYCDCACNA1GCACNA1BCACNA1CBACE1 | |
| SCHEMBL23526242 | 0.94 | MLYCD (0.36) | MLYCDCACNA1GCACNA1BCACNA1CBACE1 | |
| SCHEMBL30302011 | 0.94 | MLYCD (0.36) | MLYCDCACNA1GCACNA1BCACNA1CBACE1 | |
| SCHEMBL30014032 | 0.89 | THRA (0.33) | MLYCDCACNA1GCACNA1BCACNA1C | |
| SCHEMBL23526088 | 0.76 | MLYCD (0.43) | MLYCDEPHX2LMNA | |
| SCHEMBL29945782 | 0.76 | MLYCD (0.43) | MLYCDEPHX2LMNA | |
| SCHEMBL17050929 | 0.72 | GPR119 (0.34) | MLYCDBACE1 | |
| SCHEMBL31643114 | 0.72 | MLYCD (0.40) | MLYCDEPHX2POLB | |
| SCHEMBL28668894 | 0.72 | MLYCD (0.40) | MLYCDEPHX2POLB | |
| SCHEMBL28880360 | 0.72 | MLYCD (0.40) | MLYCDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137886-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | MLYCD 3580/4885CACNA1G 4341/4885CACNA1B 4216/4885 |
| US-11702418-B2 | SOS1 inhibitors | SOS1, SOS2, SOST | MLYCD 3920/4885CACNA1G 3977/4885CACNA1B 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.